Compare GCV & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCV | SEER |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.7M | 97.3M |
| IPO Year | 1994 | 2020 |
| Metric | GCV | SEER |
|---|---|---|
| Price | $4.66 | $2.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 50.2K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,578,000.00 |
| Revenue This Year | N/A | $2.14 |
| Revenue Next Year | N/A | $25.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.99 |
| 52 Week Low | $3.88 | $1.55 |
| 52 Week High | $4.77 | $2.41 |
| Indicator | GCV | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 72.61 |
| Support Level | $4.35 | $2.15 |
| Resistance Level | $4.77 | $2.40 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 47.06 | 81.02 |
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive, and others. All the operation of the group is operated through the regions of the United States.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.